Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer's Disease
(1) Background: TDMQ20 is a specific regulator of copper homeostasis in the brain, able to inhibit cognitive impairment in the early stages of Alzheimer's disease (AD) in mouse models of AD. To promote the further development of this drug-candidate, preliminary data on the pharmacokinetics of T...
Saved in:
Main Authors: | Lan Huang (Author), Yaoxun Zeng (Author), Yongliang Li (Author), Yingshan Zhu (Author), Yan He (Author), Yan Liu (Author), Anne Robert (Author), Bernard Meunier (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Specific Copper(II) Chelator TDMQ20 Is Efficient for the Treatment of Wilson's Disease in Mice
by: Yingshan Zhu, et al.
Published: (2023) -
Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer's Disease
by: Ignazio Schino, et al.
Published: (2022) -
Preparation and activity study of Ruoqiang jujube polysaccharide copper chelate
by: Aierpati Moheteer, et al.
Published: (2024) -
Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands
by: Fabian Krutzek, et al.
Published: (2024) -
Synergy effects of copper ion in doxorubicin-based chelate prodrug for cancer chemo-chemodynamic combination therapy
by: Wen Zhang, et al.
Published: (2023)